Home > Resources > Whitepapers > Cybersecurity of medical devices

Cybersecurity of medical devices

September 25, 2018

Increasing the connectivity of medical devices to computer networks and the convergence of technologies has exposed vulnerable devices and software applications to incidents. The need to protect patient data from cyber-attack is now well understood. However, the potential impact on clinical care and patient safety is raising concerns for healthcare organizations, regulators and medical device manufacturers alike. Control of a medical device could also be compromised.

Spotlight

Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera is focused on harnessing the potential of our proprietary technology to treat genetically defined forms of B-cell lymphomas and rare autoimmune diseases.

OTHER WHITEPAPERS

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

Accelerating the Biomanufacturing Revolution

whitePaper | February 11, 2022

The biomanufacturing revolution is here. Recent advancements in the field of synthetic biology have enabled significant cost reductions in foundational bioengineering unit operations such as DNA synthesis and sequencing.

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.